In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate ...

Trastuzumab deruxtecan showed a strong response in solid tumors with HER2 amplification via cfDNA. Skip to main content. ... Study Design and Eligibility. HERALD was a multicenter, open-label, ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki induced encouraging response rates among certain patients with early breast cancer, according to findings presented at San Antonio Breast Cancer ...

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...

Trastuzumab deruxtecan improves survival in second- and later-line settings. ... In the DESTINY-Breast02 study, ... "All had prior trastuzumab and T-DM1 by design, ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 ...

In the DESTINY-Breast04 study, the advantage of treatment with trastuzumab deruxtecan in patients with HER2-low tumors was shown in overall survival in particular: The median survival of patients ...

The median OS when using trastuzumab deruxtecan was 14.7 months compared to 11.4 months for the current standard treatment approach. Using the drug also reduced the risk of death by nearly 30% and ...

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The ...